Videos

This segment offers an up-to-date overview of current treatment standards and diagnostic practices in advanced esophageal squamous cell carcinoma (ESCC). The discussion highlights how first-line therapy for advanced ESCC increasingly combines platinum-based chemotherapy with immunotherapy, specifically PD-1 inhibitors such as nivolumab, pembrolizumab, and tislelizumab. These regimens, supported by NCCN guideline recommendations, provide new hope for improved outcomes in this challenging disease. Additionally, the segment addresses the vital role of advanced diagnostics in guiding therapy. At the time of diagnosis, Next-Generation Sequencing (NGS) and molecular profiling, including assessment of PD-L1 and MSI status, are now standard practice. This approach ensures patients receive the most effective, personalized treatments. The segment underscores how these modern strategies combine cutting-edge drugs and genetic assessment to shape a dynamic era in ESCC care.

This discussion provides an in-depth overview of the current standard of care for advanced esophageal squamous cell carcinoma (ESCC), with brief parallels to biomarker-driven gastric cancer management. Chemotherapy, most commonly fluoropyrimidine-based regimens combined with a platinum agent such as oxaliplatin or cisplatin, remains the treatment foundation, consistent with NCCN-endorsed approaches. The segment highlights the growing importance of molecular profiling, emphasizing next-generation sequencing (NGS) and immunohistochemistry for key biomarkers. In ESCC and related esophagogastric tumors, PD-L1 and mismatch repair/microsatellite instability status are central to immunotherapy decision-making, while in gastric and GEJ adenocarcinoma HER2 and claudin 18.2 have become critical targets. Experts underscore that timely biomarker testing, ideally completed before treatment initiation, guides selection of chemotherapy backbones, immunotherapy, and targeted agents, as contemporary guidelines increasingly advocate early, comprehensive evaluation. There is also mention of nuances in PD-L1 scoring (CPS vs TAP) and the need for standardized reporting across laboratories. This segment offers a practical framework for integrating testing into advanced ESCC care, with scalable lessons for gastric cancer.

Che-Kai Tsao, MD, MS, discusses the current state of treatment for metastatic hormone-sensitive prostate cancer.

A novel immune-based therapy shows 100% response rates in newly diagnosed multiple myeloma patients, highlighting its potential as a frontline treatment.

Experts discuss the evolving strategies in managing immune-related adverse events in cancer treatment, emphasizing precision immunomedicine and patient history.

Panelists analyze results from an indirect treatment comparison evaluating different combination immunotherapies in advanced melanoma.

Frederick L. Locke, MD, discusses the 2025 removal of the REMS program for CAR T-cell therapy and the resulting improvements to patient access.

Discover evolving strategies for managing immune-related adverse events in cancer immunotherapy, enhancing decision-making for oncologists and practitioners.

Panelists discuss how addressing current knowledge gaps and improving real-world integration of emerging therapies will advance care for patients with EGFR-mutant non–small cell lung cancer (NSCLC).

Join the 43rd Annual Chemotherapy Foundation Symposium in New York City for cutting-edge cancer care education and networking opportunities.

Dr. Strosberg discusses the safety profile and long-term toxicities of 212Pb-DOTAMTATE treatment, highlighting renal issues and achalasia in patients.

Dr. Michael Soulen discusses safety concerns and adverse events in neuroendocrine tumor treatments, highlighting cytopenia and radiation risks while ensuring patient safety.

A panelist discusses how novel bispecifics and ADCs signal a more hopeful future for ES-SCLC management.

Panelists discuss long-term efficacy and safety outcomes from pivotal studies evaluating dual immune checkpoint inhibition in advanced melanoma.

A panelist discusses how lurbinectedin and tarlatamab both remain essential options within evolving treatment strategies.

Chandler H. Park, MD, discusses real-world data for maintenance avelumab in bladder cancer and factors that sway his treatment selection.

Jason S. Starr, DO, discusses the significance of the extrapancreatic neuroendocrine tumor cohort of the phase 3 CABINET trial of cabozantinib.

A novel treatment combining chemotherapy and PRRT shows promising safety and efficacy for neuroendocrine tumors, with high response rates and ongoing trials.

Panelists discuss how dose optimization and personalized adjustment strategies sustain efficacy and enhance long-term outcomes in EGFR-mutant NSCLC.

Panelists discuss how proactive adverse event prevention and patient support improve tolerability and continuity of targeted treatment in EGFR-mutant non–small cell lung cancer (NSCLC).

Experts explore a novel combined therapy for liver-dominant neuroendocrine tumors, enhancing treatment durability with chemotherapy and PRRT.

Dr. Jonathan Strosberg discusses the promising results of the ALPHAMEDIX-02 trial, evaluating a new therapy for advanced neuroendocrine tumors.

Vivek Subbiah emphasizes tumor-agnostic therapies' potential to revolutionize cancer treatment by targeting genetic biomarkers, ensuring equitable access to precision medicine.

Experts discuss the importance of collaboration in improving surgical standards and treatment outcomes for neuroendocrine tumors through the CUTNETs initiative.

Healthcare professionals adjust octreotide and lanreotide doses for effective symptom control in patients with carcinoid syndrome, following NCCN guidelines.

Mary Maluccio, MD, MPH, FACS, discusses the promising next steps for 212Pb-DOTAMTATE in treating GEP-NETs, including a pivotal phase 3 trial and ongoing patient follow-up.

Dr Mary Maluccio discusses promising results and safety concerns from the ALPHAMEDIX-02 trial on innovative therapy for GEP-NETs.

A panelist discusses how proactive management of CRS and ICANS supports safe community use of DLL3-targeted therapy.

A panelist discusses how tarlatamab’s strong efficacy data suggest a practice-changing advance for relapsed ES-SCLC.

Panelists discuss current frontline therapeutic strategies for advanced melanoma, highlighting the rationale and evolution of combination immunotherapy approaches.